| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
HLB Life Science Co. Ltd (KQ: 067630)
067630 Technical Analysis
5
| As on 4th Nov 2025 067630 STOCK Price closed @ 4770.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 10166.35 & Strong Sell for SHORT-TERM with Stoploss of 11116.55 we also expect STOCK to react on Following IMPORTANT LEVELS. |
067630STOCK Price
| Open | 5000.00 | Change | Price | % |
| High | 5200.00 | 1 Day | 765.00 | 19.10 |
| Low | 4650.00 | 1 Week | 285.00 | 6.35 |
| Close | 4770.00 | 1 Month | 1330.00 | 38.66 |
| Volume | 11595840 | 1 Year | -12030.01 | -71.61 |
| 52 Week High 17210.01 | 52 Week Low 3235.00 | ||||
KQ Korea Most Active Stocks
| 032980 | 302.00 | 16.15% |
| 049630 | 1400.00 | 9.38% |
| 010170 | 2565.00 | -8.72% |
| 001520 | 881.00 | 5.38% |
| 001520 | 881.00 | 5.38% |
| 256840 | 6050.00 | 18.16% |
| 043220 | 171.00 | -29.63% |
| 006340 | 4255.00 | 0.83% |
| 006340 | 4255.00 | 0.83% |
| 000040 | 670.00 | 12.42% |
KQ Korea Top Gainers Stocks
KQ Korea Top Losers Stocks
| 067630 Daily Charts |
067630 Intraday Charts |
Whats New @ Bazaartrend |
067630 Free Analysis |
|
|
067630 Important Levels Intraday
| RESISTANCE | 5829.85 |
| RESISTANCE | 5489.95 |
| RESISTANCE | 5279.85 |
| RESISTANCE | 5069.75 |
| SUPPORT | 4470.25 |
| SUPPORT | 4260.15 |
| SUPPORT | 4050.05 |
| SUPPORT | 3710.15 |
067630 Forecast November 2025
| 4th UP Forecast | 23365.6 |
| 3rd UP Forecast | 17401.9 |
| 2nd UP Forecast | 13715.6 |
| 1st UP Forecast | 10029.3 |
| 1st DOWN Forecast | -489.26 |
| 2nd DOWN Forecast | -4175.56 |
| 3rd DOWN Forecast | -7861.86 |
| 4th DOWN Forecast | -13825.6 |
067630 Weekly Forecast
| 4th UP Forecast | 10242.70 |
| 3rd UP Forecast | 8487.57 |
| 2nd UP Forecast | 7402.69 |
| 1st UP Forecast | 6317.81 |
| 1st DOWN Forecast | 3222.19 |
| 2nd DOWN Forecast | 2137.31 |
| 3rd DOWN Forecast | 1052.43 |
| 4th DOWN Forecast | -702.70 |
067630 Forecast2025
| 4th UP Forecast | 32990.9 |
| 3rd UP Forecast | 23940.3 |
| 2nd UP Forecast | 18345.9 |
| 1st UP Forecast | 12751.5 |
| 1st DOWN Forecast | -3211.53 |
| 2nd DOWN Forecast | -8805.92 |
| 3rd DOWN Forecast | -14400.3 |
| 4th DOWN Forecast | -23450.9 |
HLB Life Science Co. Ltd ( KQ Korea Symbol : 067630 )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
067630 Business Profile
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea. Address: 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, South Korea
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service